Detection Of ESR1 Mutations In Baseline ctDNA Tied To Inferior PFS And OS In Patients With Advanced HR-Positive Breast Cancer Treated With Exemestane Versus Fulvestrant, Study Indicates

Cancer Network (10/21, Slater) reports researchers found in “a combined analysis of the phase 3 SoFEA and EFECT trials” that “detection of ESR1 mutations in baseline circulating tumor DNA (ctDNA) is associated with inferior progression-free survival (PFS)...